Working Group 2

Extension to other gut compartments and host interactions

Objectives and Activities

WG2 aims to expand the application of in vitro gut models beyond the colon by integrating microbiota-host interactions across various gastrointestinal compartments and target organs. This includes exploring models that connect upper GI regions (oral cavity, stomach, small intestine) with the colon, integrating host cells (intestinal, hepatic, pulmonary, neural), and incorporating in silico tools for predictive modelling. WG2 also addresses the miniaturization of models to allow for high-throughput screening and focuses on evaluating the in vitroin vivo correlation (IVIVC) of these systems. This integrated approach will foster the development of physiologically representative models that can better mimic host–microbiome dynamics in both health and disease.

Working group leaders

Clarisse Nobre

WG2 Leader
University of Minho, Braga

Anthony Buckley

WG2 Co-leader
University of Leeds

Tasks

Task 2.1.

Connection to upper GI tract

Task 2.2.

Coupling with host cells

Task 2.3.

Miniaturization of in vitro models

Task 2.4.

In silico gut models

Task 2.5.

In vitro–in vivo correlations (IVIVC)

Deliverables

D2.1

Map of the current in vitro models integrating microbiota in the upper GI tract + peer-reviewed publication – Due time at month15

D2.2

Report on guidelines to implement microbiota in upper GI tract in vitro models – Due time at month 21

D2.3

Report on guidelines to couple upper/lower GI tract models and/or host cells – Due time at month 30

D2.4

Symposium/training for young scientists on WG2 activities – Due time at month 36

Working group meetings

COST

COST (European Cooperation in Science and Technology) is a funding agency for research and innovation networks. Our Actions help connect research initiatives across Europe and enable scientists to grow their ideas by sharing them with their peers. This boosts their research, career and innovation. (www.cost.eu)

COST Action CA23110

Scientific literature is shedding light on the centrality of GI for human health and wellbeing. Indeed, the physiologic effects of nutrients, bioactives and even toxic compounds (including foodborne pathogens) are mediated by their absorption rate in the intestine and by their interaction with gut microbiota and its host ecosystem. Testing food, feed, supplements or drugs in clinical studies gives rise to ethical issues, and the transferability of animal data across species is often problematic because of differences in physiology, metabolism and chemical susceptibilities.

MoU
062/22

CSO Approval Date
27/05/2022

Start Date
06/10/2022

End Date
05/10/2026

2025 | Cost Action CA23110 | All Right Reserved  | Design by Onno Media